GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Conba Pharmaceutical Co Ltd (SHSE:600572) » Definitions » ROC %

Zhejiang Conba Pharmaceutical Co (SHSE:600572) ROC % : 6.29% (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Zhejiang Conba Pharmaceutical Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Zhejiang Conba Pharmaceutical Co's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was 6.29%.

As of today (2024-12-13), Zhejiang Conba Pharmaceutical Co's WACC % is 9.54%. Zhejiang Conba Pharmaceutical Co's ROC % is 7.84% (calculated using TTM income statement data). Zhejiang Conba Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Zhejiang Conba Pharmaceutical Co ROC % Historical Data

The historical data trend for Zhejiang Conba Pharmaceutical Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Conba Pharmaceutical Co ROC % Chart

Zhejiang Conba Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.10 7.12 10.33 8.76 11.31

Zhejiang Conba Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.59 3.74 13.36 8.81 6.29

Zhejiang Conba Pharmaceutical Co ROC % Calculation

Zhejiang Conba Pharmaceutical Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=845.287 * ( 1 - 12.11% )/( (6662.995 + 6476.228)/ 2 )
=742.9227443/6569.6115
=11.31 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10931.368 - 1800.341 - ( 2468.032 - max(0, 2789.113 - 5395.472+2468.032))
=6662.995

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11238.242 - 2192.005 - ( 2570.009 - max(0, 3172.538 - 5775.318+2570.009))
=6476.228

Zhejiang Conba Pharmaceutical Co's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=502.928 * ( 1 - 15.97% )/( (6622.178 + 6806.184)/ 2 )
=422.6103984/6714.181
=6.29 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10254.458 - 2244.439 - ( 1387.841 - max(0, 2755.047 - 4889.093+1387.841))
=6622.178

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9749.198 - 2139.853 - ( 803.161 - max(0, 2458.374 - 4352.429+803.161))
=6806.184

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Conba Pharmaceutical Co  (SHSE:600572) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Zhejiang Conba Pharmaceutical Co's WACC % is 9.54%. Zhejiang Conba Pharmaceutical Co's ROC % is 7.84% (calculated using TTM income statement data). Zhejiang Conba Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Zhejiang Conba Pharmaceutical Co ROC % Related Terms

Thank you for viewing the detailed overview of Zhejiang Conba Pharmaceutical Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Conba Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 568 Binkang Road, New and High-Technology Development Zone, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
Executives
Hu Ji Qiang Director
Yuan Zhen Xian senior management
Yin Shi Shui Supervisors
Xu Chun Ling senior management
Jin Zu Cheng Directors, senior managers
Ye Jian Feng Supervisors
Ying Chun Xiao Director
Chen Ming Director
Luo Guo Liang Director
Wu Zhong Shi Supervisors
Wang Ru Wei Director
Yang Jun De senior management
Yang Xian Min senior management
Chen Yue Zhong senior management
Li Jian Zhong Supervisors

Zhejiang Conba Pharmaceutical Co Headlines

No Headlines